Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax Extension Study
NCT03844048Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Sep 2019
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 23
01
Overview
A Phase 3 trial of venetoclax in chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), multiple myeloma (MM), non-Hodgkin lymphoma (NHL), acute lymphoblastic leukemia (ALL), sponsored by AbbVie Inc.. Started Sep 2019; status: active, not recruiting.
02
Drugs
venetoclax
03
Conditions
chronic lymphocytic leukemia (CLL)acute myeloid leukemia (AML)multiple myeloma (MM)non-Hodgkin lymphoma (NHL)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03844048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03844048.